CURRENT ISSUE
July, 2021
No. 106 (7)
2020 Impact Factor: 9.941
Submission > Acceptance: 52 days
EDITOR'S PICKS
ARTICLES IN THREE SENTENCES
Article
Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial
This prospective study evaluated reduced intensity conditioning hematopoietic stem cell transplantation (HSCT) followed by a preemptive minimal residual disease (MRD)-driven immune-intervention. MRD-negative status at 12 months was achieved in 64% of patients versus 14.2% before HSCT. These data argue for the benefit of an early preemptive immune-intervention based on MRD evaluation.
Case Report
Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of Waldenström macroglobulinemia in two cases
The authors report two cases with IgMκ monoclonal gammopathy visible as a small peak on serum protein electrophoresis and a high level of serum-free light chains revealing μ-heavy chain disease associated with Waldenström macroglobulinemia. Rituximab with bortezomib and cyclophosphamide + dexamethasone allowed a complete response in one patient.
Article
In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor
This study reports the discovery of a novel class of orally bioavailable DNA methyltransferase 1 (DNMT1) selective inhibitors as exemplified by GSK3482364. This molecule does not require DNA incorporation and its effect is reversible. In preclinical models, selective, reversible inhibition of DNMT1 was well-tolerated and induced HbF.
Article
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression
Angiogenic switching is a key process during transition from monoclonal gammopathy of undetermined significance to multiple myeloma (MM). This study demonstrated that the junctional adhesion molecule-A (JAM-A) is an important mediator of MM progression through facilitating MM-associated angiogenesis. JAM-A-blocking monoclonal antibodies impaired MM progression and decreased MM vascularity in mice.
TAKE ADVANTAGE FROM HAEMATOLOGICA
